ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Agilent Technologies has acquired two small firms to expand its life sciences offerings. One purchase is Lab901, an Edinburgh, Scotland-based maker of electrophoresis equipment. The 10-year-old firm’s automated benchtop instruments are used for DNA, RNA, and protein analysis. Agilent has also acquired Wakefield, Mass.-based Biocius Life Sciences, a two-year-old spinoff of BioTrove. The company sells the RapidFire high-throughput mass spectrometry drug-screening platform. All 45 Lab901 employees and all 25 from Biocius will join Agilent.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X